GlassScriptPhysician profile
Mark J Granada
NPI 1467642504
$6,794.11
in general payments reported to CMS, 2019-2025
31 companies · $708 in 2025
The $708 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,216 · 2020: $592 · 2021: $148 · 2022: $2,014 · 2023: $1,406 · 2024: $711 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,807 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,806.53 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,287.24 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Genzyme Corporation | $732.27 | 2019-2024 | |
| Glaxosmithkline, LLC. | $724.31 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inari Medical, INC. | $555.89 | 2020-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amgen INC. | $536.70 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.69 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $241.71 | 2019-2025 | Arikayce |
| Genentech USA, INC. | $221.00 | 2019-2023 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $212.05 | 2020-2023 | Glassia |
| Baxter Healthcare | $191.60 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Pulmonx Corporation | $187.43 | 2024-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| United Therapeutics Corporation | $168.94 | 2022-2023 | Tyvaso |
| Mylan Specialty L.P. | $165.71 | 2019-2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $149.66 | 2019-2023 | Xarelto |
| Grifols USA, LLC | $146.61 | 2019-2023 | Prolastin-C Liquid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $139.26 | 2019-2025 | Opsumit |
| Regeneron Healthcare Solutions, INC. | $91.25 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $76.39 | 2019-2024 | |
| Verona Pharma, INC. | $65.50 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $63.86 | 2023 | Acthar |
| Teva Pharmaceuticals USA, INC. | $59.82 | 2019-2023 | |
| Circassia INC. | $48.93 | 2019-2020 | |
| Philips North America LLC | $45.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $42.99 | 2022 | |
| Electromed, INC. | $32.01 | 2019-2024 | Smartvest |
| Vapotherm INC | $21.90 | 2022 | |
| Sunovion Pharmaceuticals INC. | $21.66 | 2019 | |
| Ethicon US, LLC | $20.58 | 2022 | |
| Merck Sharp & Dohme LLC | $15.63 | 2020 | |
| Inogen, INC. | $15.32 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| E.R. Squibb & Sons, L.L.C. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Granada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.